Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-11-07 DOI:10.3324/haematol.2024.285805

Marta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, Alberto Hernández Sánchez, Javier Martinez Elicegui, Teresa González, Raúl Azibeiro Melchor, María Abáigar, Laura Tur, Daniele Dall'Olio, Eric Sträng, Jesse M Tettero, Gastone Castellani, Axel Benner, Konstanze Döhner, Christian Thiede, Klaus H Metzeler, Torsten Haferlach, Frederik Damm, Rosa Ayala, Joaquín Martínez-López, Ken I Mills, Jorge Sierra, Sören Lehmann, Matteo G Della Porta, Jiri Mayer, Dirk Reinhardt, Rubén Villoria Medina, Renate Schulze-Rath, Martje Barbus, Jesús María Hernández-Rivas, Brian J P Huntly, Gert Ossenkoppele, Hartmut Döhner, Lars Bullinger

{"title":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.","authors":"Marta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, Alberto Hernández Sánchez, Javier Martinez Elicegui, Teresa González, Raúl Azibeiro Melchor, María Abáigar, Laura Tur, Daniele Dall'Olio, Eric Sträng, Jesse M Tettero, Gastone Castellani, Axel Benner, Konstanze Döhner, Christian Thiede, Klaus H Metzeler, Torsten Haferlach, Frederik Damm, Rosa Ayala, Joaquín Martínez-López, Ken I Mills, Jorge Sierra, Sören Lehmann, Matteo G Della Porta, Jiri Mayer, Dirk Reinhardt, Rubén Villoria Medina, Renate Schulze-Rath, Martje Barbus, Jesús María Hernández-Rivas, Brian J P Huntly, Gert Ossenkoppele, Hartmut Döhner, Lars Bullinger","doi":"10.3324/haematol.2024.285805","DOIUrl":null,"url":null,"abstract":"<p><p>Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.285805","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.

查看原文本刊更多论文

急性髓性白血病强化治疗的疗效：对 HARMONY 联盟二十年数据的分析。

自2017年以来，靶向疗法与传统强化化疗相结合，开始改善急性髓性白血病（AML）患者的治疗效果。然而，即使在这些创新之前，强化化疗的疗效也有所改善，而这一点尚未得到广泛研究。因此，我们利用 HARMONY 联盟的大型泛欧多中心数据集来评估二十年来与治疗时间相关的疗效。在 5359 例急性髓细胞白血病患者中，我们比较了强化诱导治疗对 1997 年至 2016 年连续 4 个 5 年日历期间的疗效的影响。在此期间，急性髓细胞性白血病患者的 5 年生存率显著提高，不同遗传风险组的情况也是如此。特别是，随着时间的推移，60 天死亡率从 13.0% 降至 4.7%。多变量模型证实了日历期对结果的独立影响。患者的病情均有改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.